Thomas Slavin, MD, FACMGG, DABMD
Speaker

Quest Diagnostics
Biography
Dr. Thomas Slavin is a physician-scientist and biotech executive, triple-board-certified in clinical genetics, molecular diagnostics and pediatrics. He is chief clinical officer of Molecular Oncology and Medical Director of Haystack Oncology at Quest Diagnostics. He previously held the positions of chief medical officer at Myriad Genetics and chief scientific officer at HALO Precision Diagnostics. He was a former assistant professor in the departments of Medical Oncology and Population Sciences at City of Hope National Medical Center.
Dr. Slavin graduated medical school with Alpha-Omega-Alpha-honors from the University of South Florida. He completed his residency programs at Case Western Reserve in Cleveland, Ohio where his training included a postdoctoral research year in genetic epidemiology. He has also completed graduate coursework toward a master’s degree in clinical research through the University of Southern California and holds a master’s in business administration through Columbia Southern University.
He is a clinical advisor for the breast screening awareness nonprofit Touch4Life. He is an active member of the American Association of Cancer Research, the American Society of Clinical Oncology (ASCO), the American Society of Human Genetics, the Collaborative Group of the Americas on Inherited Colorectal Cancer and is a fellow of the American College of Medical Genetics and Genomics. He has served on National Comprehensive Cancer Network (NCCN) committees for both the genetics of and screening for colorectal cancer. He has served on three ClinGen expert working group committees for variant classification of breast, gastrointestinal and ovarian cancer predisposition genes. Focused on expanding genetics education for cancer care providers, Dr. Slavin is an active faculty member of City of Hope’s hereditary genomics training program. He is a well-respected researcher in the field of medical genetics, publishing over 80 journal articles collectively evaluating genomic data from over 500,000 patients, multiple book chapters and providing numerous presentations at national and international medical meetings. He has been involved in many national cancer research grants and was a 2018 National Institutes of Health (NIH) K08-career development grant awardee.